ClinicalTrials.gg
RecruitingNCT06254300On4CancerUpdated Feb 12, 2024

Online Exercise Program During Perioperative Treatment in Adults With Gastric Cancer

An interventional study of Exercise Training in Gastric Cancer, sponsored by University of Maia. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-12.

Sponsored by University of Maia · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 10 months after the study started (first participant enrolled Mar 2022, registered Jan 2024).
  • Started Mar 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Stomach Neoplasms with a site in Portugal — 6 open to participants now, 11 under way, 4 of them phase 3. Stomach Neoplasms · Portugal.

Planned enrollment
29th of 31
40 · median 296
Started
2022
with 4 others
No phase
5 of 41
4 open now
Primary completion
2025-07
later than 2 of 10 live
Registered
36th of 41
by date

Among the 41 studies in Stomach Neoplasms with a site in Portugal, this one is the 29th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2022, is one of 5 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 36th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 41 studies in Stomach Neoplasms with a site in Portugal are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Stomach Neoplasms with a site in Portugal, or all of them as a file.
02

Study summary

Perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT4) is the standard perioperative treatment for resectable and advanced gastric adenocarcinoma. Although the FLOT4 regimen have shown increases in the overall survival, response rate, and progression-free survival, it is also associated with substantial toxicities. Prehabilitation is an effective strategy to improve physical fitness in cancer patients and reverse functional limitations and inadequate levels of physical activity that are associated with worse postoperative outcomes and treatment response. Therefore, the main objective of this study is to evaluate the effects of an online, supervised exercise-based prehabilitation program on the cardiorespiratory fitness level, functional fitness and quality of life among adults with gastric cancer undergoing neoadjuvant chemotherapy.

03

Conditions studied

  • Gastric Cancer

Keywords

  • Physical Exercise
  • Gastric Cancer
  • Prehabilitation
  • Perioperative Cancer Treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Willingness to participate in the study.
  • Referral for surgical treatment for gastric cancer.
  • Diagnosis of gastric cancer for curative intent - stage II/III
  • Referall to the perioperative FLOT4 chemotherapy regimen
  • PS 0-1.
  • Receptiveness and availability to use the proposed technology for exercise sessions

Exclusion criteria

Exclusion Criteria:

  • Inability to provide
  • Inability to engage in physical training or perform the baseline walking test
  • Presence of distant disease
  • History of previous or concurrent
  • Diagnosis of heart failure, ischemic heart disease, or sinus node valvular disease
  • Pregnancy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    The intervention group will participate in a supervised online exercise prehabilitation program that will extend throughout the chemotherapy until one week before the scheduled surgery. The exercise program will consist of three sessions per week, each lasting 60 minutes. The design of the prehabilitation program is based on exercise prescription recommendations for cancer survivors and will be tailored to each patient's initial functional capacity. The exercise sessions will be conducted at home through an online platform, enabling real-time interaction among groups of patients.

    Behavioral: Exercise Training

  • No intervention
    Control Group

    Participants from the control group will be offered optimal medical care, which includes general advice about healthy lifestyle including regular physical activity participation according to the current guidelines.

Interventions

  • BehavioralExercise Training

    The exercise program will consist of three sessions per week, each lasting 60 minutes. The aerobic exercise will gradually increase the duration throughout the program to 40 minutes and exercise intensity from 30% to 59% of heart rate reserve. The resistance training will include bodyweight functional exercises and resistance exercises using elastic bands. The intensity of resistance exercise will progressively increase according to levels of progressive length and resistance of the elastic bands. The volume of resistance training will start with one set of 8 repetions. It will then gradually increase alongside the program to 2 sets of 12 repetitions. Participants will also be guided to assess their subjective effort using the Borg scale (RPE 12-15).

06

What researchers measure

Primary outcomes

  1. Aerobic capacity

    Incremental Shuttle Walk Test (ISWT)

    Time frame: Change from baseline to 1 week before surgery

Secondary outcomes

  1. Aerobic capacity

    Incremental Shuttle Walk Test (ISWT)

    Time frame: Change from 1 week before surgery to 30 days post-surgery

  2. Aerobic capacity

    Incremental Shuttle Walk Test (ISWT)

    Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment

  3. Muscle strength

    Digital hand dynamometer

    Time frame: Change from baseline to 1 week before surgery

  4. Muscle strength

    Digital hand dynamometer

    Time frame: Change from 1 week before surgery to 30 days post-surgery

  5. Muscle strength

    Digital hand dynamometer

    Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment

  6. Body composition

    Bioelectrical impedance

    Time frame: Change from baseline to 1 week before surgery

  7. Body composition

    Bioelectrical impedance

    Time frame: Change from 1 week before surgery to 30 days post-surgery

  8. Body composition

    Bioelectrical impedance

    Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment

  9. Health-related quality of life

    European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The final scores will range from 0 to 100, with higher scores on the functional scales representing a high level of functioning and higher scores on the symptom scales implying a stronger symptom burden.

    Time frame: Change from baseline to 1 week before surgery

  10. Health-related quality of life

    European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The final scores will range from 0 to 100, with higher scores on the functional scales representing a high level of functioning and higher scores on the symptom scales implying a stronger symptom burden.

    Time frame: Change from 1 week before surgery to 30 days post-surgery

  11. Health-related quality of life

    European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The final scores will range from 0 to 100, with higher scores on the functional scales representing a high level of functioning and higher scores on the symptom scales implying a stronger symptom burden.

    Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment

  12. Gastric cancer specific health-related quality of life

    The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach (EORTC QLQ-STO22). The final scores will range from 0 to 100, with higher scores indicating worse symptomatic problems.

    Time frame: Change from baseline to 1 week before surgery

  13. Gastric cancer specific health-related quality of life

    The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach (EORTC QLQ-STO22). The final scores will range from 0 to 100, with higher scores indicating worse symptomatic problems.

    Time frame: Change from1 week before surgery to 30 days post-surgery

  14. Gastric cancer specific health-related quality of life

    The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach (EORTC QLQ-STO22). The final scores will range from 0 to 100, with higher scores indicating worse symptomatic problems.

    Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment

  15. Physical activity

    Accelerometer (wGT3X, ActiGraph LLC, Pensacola, FL, USA)

    Time frame: Change from baseline to 1 week before surgery

  16. Physical activity

    Accelerometer (wGT3X, ActiGraph LLC, Pensacola, FL, USA)

    Time frame: Change from 1 week before surgery to 30 days post-surgery

  17. Physical activity

    Accelerometer (wGT3X, ActiGraph LLC, Pensacola, FL, USA)

    Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment

  18. Calf circumference

    Time frame: Change from baseline to 1 week before surgery

  19. Calf circumference

    Time frame: Change from 1 week before surgery to 30 days post-surgery

  20. Calf circumference

    Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment

  21. Postoperative morbidity outcomes

    Clavien-Dindo classification

    Time frame: Within 30 days after surgery

  22. Treatment compliance

    Relative dose intensity, calculated as the ratio of the delivered dose intensity to the standard dose intensity

    Time frame: Through chemotherapy completion

  23. Adverse events

    Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Time frame: During the treatment (neoadjuvant chemotherapy)

  24. Number of hospitalizations

    Time frame: Within 30 days after surgery

  25. Length of hospital stay

    Time frame: Within 30 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jul 2025, 40 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 40 months is above that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 12, 2024
StartActual
Mar 23, 2022
Primary completionEst.
Jul 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Feb 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06254300
Lead sponsor
University of Maia
Responsible party
Lia Bahut (Principal Investigator, University of Maia) — Principal investigator
First posted
Feb 12, 2024
Start date
Mar 23, 2022
Primary completion
Jul 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Feb 12, 2024

Study contacts

Lia F Bahut, MSc
Contact
lia.bahut@gmail.com
+351 22 986 6000
Alberto Alves, PhD
Contact
ajalves@ismai.pt
+351 22 986 6000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion